Merck & Co’s Keytruda gets new colorectal cancer use after month-long FDA review

It’s barely a month since Merck & Co unveiled trial results showing that cancer immunotherapy Keytruda (pembrolizumab) works in colorectal cancer patients with certain mutations, and the FDA has already added the new indication to its label after a speedy review.